|
Post by agedhippie on Aug 7, 2017 18:52:11 GMT -5
I do not think there is any possibility they are taking shares from equity holders. I think the idea is that delisting from TASE somehow frees shares can be sold. Over at SA, one of the comment posters suggested that possibly "they couldn't issue the 10 million authorized preferred shares on the balance sheet ahead of the common while listed on TASE". See comment section of this article seekingalpha.com/article/4095774-mannkind-afrezza-scripts-dipMike mentioned on the call that delisting from the tase opens the possibility of the preferred shares. The 10q states the tase shares will trade on the Nasdaq once the delisting is final I cannot find any reference to the TASE in the 10Q. It may be that the condition of listing on the TASE was not to preempt the common stock with pref, I really don't know.
|
|
|
Post by dreamboatcruise on Aug 7, 2017 18:52:47 GMT -5
Is it official now that Buffet is the new Unicorn and Amgen is out?
I have to know what to put on my wish list that I slip under the pillow for the tooth fairy.
|
|
|
Post by peppy on Aug 7, 2017 18:57:42 GMT -5
Is it official now that Buffet is the new Unicorn and Amgen is out? I have to know what to put on my wish list that I slip under the pillow for the tooth fairy. no, I say it is not official. I want to rule out Buffet, see Amgen, and raise you Apple, (Tim Cook, glucose levels, non-invasive continuing glucose monitors and all) TEVA is stupid I guess.
|
|
|
Post by traderdennis on Aug 7, 2017 19:01:56 GMT -5
If only he knew something about investing in companies and just did that with MNKD. Too bad Deerfield has Danbury as collateral if Buffet only knows how to do real estate deals. But this is highly likely given that MNKD hasn't mentioned it... sometimes saying nothing says a lot. Only a white knight looking to do something good for humanity would give MNKD the $200M they put into the plant. At the same time getting in on the greatest advance in diabetes care in 95 years probably has Buffet's attention. I think Mike can make that elevator pitch. Its like peanut butter and jelly. Buffet's got $100B he needs to do something with and MNKD needs a couple hundred $Million. Mike would be doing Buffet the favor by giving him this opportunity. Buffet is letting the Bill Gates foundation give away his money. Doubtful if this gets past the first step
|
|
|
Post by madog365 on Aug 7, 2017 19:02:06 GMT -5
What a great call!
The team seemed more confident than ever with 4 executives presenting plans with a long term strategic outlook.
The lack of mention about the middle east combined with the pull out from TASE with 10M new preferred shares leads me to believe the two could be connected in some way.
Two separate investor meetings planned for September - What could that be all about? Finally the team wants to show some transparency. I also enjoyed the fact that the call actually lasted over an hour with the team sounding very sincere and open.
Overall i continue to be excited about the future here. Not a chance in hell i would sell my shares anywhere near these levels regardless of how loud our short friends get with their scare tactics.
GLTA, patient will win out.
|
|
|
Post by n8 on Aug 7, 2017 19:05:25 GMT -5
What a great call! The team seemed more confident than ever with 4 executives presenting plans with a long term strategic outlook. The lack of mention about the middle east combined with the pull out from TASE with 10M new preferred shares leads me to believe the two could be connected in some way. Two separate investor meetings planned for September - What could that be all about? Overall i continue to be excited about the future here. Not a chance in hell i would sell my shares anywhere near these levels regardless of how loud our short friends get with their scare tactics. GLTA, patient will win out. If I had any extra cash I would be buying the hell out of mnkd.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 7, 2017 19:09:32 GMT -5
I recorded and transcribed the important part about the Capitalization of the Company
We have many options on the table for sources of capital:
• Issue Debt
• Issue Equity
• Sale/Lease/Buy-back of our manufacturing plant in Connecticut
• Development deals that Ray and I have been working on, as well as
• International license opportunities
We have to figure out the right combination of all this mix in terms of how much capital do you want to raise to get to what time-point, so you can maximize shareholder impact, the growth of the company and the investment. But, I can confidently say at this point, that the more capital we put in, the faster we will grow Afrezza. And there is always a balance of shareholder returns, as we think about the types of mixes we have and opportunities we have to bring in capital, but also delaying a little bit the value of this investment, while we fix the fundamentals of the company was important. No matter how hard we pushed over the past 12 months, we had to fix some of the fundamental aspects of the commercial launch around the packaging, the sampling, the training of our salesforce, and how we roll this out to customers. That just took time, and we’re finally through that. And, I think you can see in Q2 of this year our first full quarter with our expanded sales team, getting growth, quarter over quarter. And I know, and many people know in the pharmaceutical industry, that to see that kind of growth in the first 3 months of a new sales team doesn’t always happen, especially on a re-launch. So, we’re very optimistic as we go forward. There’s nothing I’ve heard in the market research that tells me we’re not going to make this drug phenomenally successful. So, you’re given guidance for the first time on the history of this company, which I think is important. You can refer back to the C section to get that guidance. But, we continue to meet with potential investors and we’ll come up with the right capital solution for the company, which may or may not meet the short term vs, long term needs, or exceed the short term to get to the long term needs. But, we’ll continue to work with our potential future investors and our current equity and debt holders to get there. We will deliver on the financial commitment and we will capitalize for future growth. We expect our current capital, depending on which way we handle our Deerfield debt, to get us pretty close to into 2018. I will continue to evaluate that as we move forward after we’ve given you our expense burn quarter over quarter. Etc.
|
|
|
Post by peppy on Aug 7, 2017 19:13:51 GMT -5
|
|
|
Post by dreamboatcruise on Aug 7, 2017 19:23:13 GMT -5
I recorded and transcribed the important part about the Capitalization of the Company
We have many options on the table for sources of capital:
• Issue Debt
• Issue Equity
• Sale/Lease/Buy-back of our manufacturing plant in Connecticut
• Development deals that Ray and I have been working on, as well as
• International license opportunities
We have to figure out the right combination of all this mix in terms of how much capital do you want to raise to get to what time-point, so you can maximize shareholder impact, the growth of the company and the investment. But, I can confidently say at this point, that the more capital we put in, the faster we will grow Afrezza. And there is always a balance of shareholder returns, as we think about the types of mixes we have and opportunities we have to bring in capital, but also delaying a little bit the value of this investment, while we fix the fundamentals of the company was important. No matter how hard we pushed over the past 12 months, we had to fix some of the fundamental aspects of the commercial launch around the packaging, the sampling, the training of our salesforce, and how we roll this out to customers. That just took time, and we’re finally through that. And, I think you can see in Q2 of this year our first full quarter with our expanded sales team, getting growth, quarter over quarter. And I know, and many people know in the pharmaceutical industry, that to see that kind of growth in the first 3 months of a new sales team doesn’t always happen, especially on a re-launch. So, we’re very optimistic as we go forward. There’s nothing I’ve heard in the market research that tells me we’re not going to make this drug phenomenally successful. So, you’re given guidance for the first time on the history of this company, which I think is important. You can refer back to the C section to get that guidance. But, we continue to meet with potential investors and we’ll come up with the right capital solution for the company, which may or may not meet the short term vs, long term needs, or exceed the short term to get to the long term needs. But, we’ll continue to work with our potential future investors and our current equity and debt holders to get there. We will deliver on the financial commitment and we will capitalize for future growth. We expect our current capital, depending on which way we handle our Deerfield debt, to get us pretty close to into 2018. I will continue to evaluate that as we move forward after we’ve given you our expense burn quarter over quarter. Etc.
This was the tongue twist. Seeing it written makes me feel a little better. It appears that what he meant to say was the second attempt having realized the first came out wrong. The first makes it seem they aren't confident in meeting short term needs. The latter seems to imply they are confident in at least another can kick to get down the road a bit further but don't rule out something bigger. That is about as good as I'd expect on this call. Wish that slip hadn't happened, however, since it left at least one person scratching their head.
|
|
|
Post by dreamboatcruise on Aug 7, 2017 19:29:42 GMT -5
What a great call! The team seemed more confident than ever with 4 executives presenting plans with a long term strategic outlook. The lack of mention about the middle east combined with the pull out from TASE with 10M new preferred shares leads me to believe the two could be connected in some way. Two separate investor meetings planned for September - What could that be all about? Overall i continue to be excited about the future here. Not a chance in hell i would sell my shares anywhere near these levels regardless of how loud our short friends get with their scare tactics. GLTA, patient will win out. If I had any extra cash I would be buying the hell out of mnkd. I'd have lots of extra cash... if I hadn't already bought the hell out of MNKD
|
|
|
Post by sayhey24 on Aug 7, 2017 19:38:04 GMT -5
A lot can happen in 4 months including some sales. Its got to be driving all those who predicted BK tomorrow, next week or next month absolutely crazy. Some how MNKD keeps moving forward and now they actually seem to have a plan and some traction. The analysts showing up was surprising and they actually seemed positive on the direction.
I was surprised. I was anticipating a disaster.
|
|
|
Post by dreamboatcruise on Aug 7, 2017 19:39:39 GMT -5
What a great call! The team seemed more confident than ever with 4 executives presenting plans with a long term strategic outlook. The lack of mention about the middle east combined with the pull out from TASE with 10M new preferred shares leads me to believe the two could be connected in some way. Two separate investor meetings planned for September - What could that be all about? Finally the team wants to show some transparency. I also enjoyed the fact that the call actually lasted over an hour with the team sounding very sincere and open. Overall i continue to be excited about the future here. Not a chance in hell i would sell my shares anywhere near these levels regardless of how loud our short friends get with their scare tactics. GLTA, patient will win out. Apple has stores in the UAE, so given the lack of mention of Apple, the only logical conclusion is that they are involved as well as an investor or something. "Siri, we're lost, how do we steer this ship to the UAE?"
|
|
|
Post by sportsrancho on Aug 7, 2017 19:40:28 GMT -5
I thought the call was good. Mike did a great job and Ray IMO did the best he has ever done. No BS.. Loved the answers to the analysts questions! Loved that there were analysts! Maybe, fingers crossed we get a up-grade:-) Town Hall next month. Liked that too. Kids Ped starts in Sept. Guidance for the first time. Re-fills addressed. A lot of balls in the air, but clearly excitement. Proud of our team:-)
|
|
|
Post by peppy on Aug 7, 2017 19:47:58 GMT -5
Gross revenue from product sales $ 4,268,000 in six months 2017,
guidance, a big jump. (analyst plants) from 4.2 million in sales /6 months to 9-14 million in the next six months. What is the increase there?
|
|
|
Post by mango on Aug 7, 2017 19:58:59 GMT -5
Best call since I have been around to hear.
Mike is a great CEO and clearly loves where he is at.
Great future to look forward to.
I love MannKind.
What else is there is say?
😎
|
|